Literature DB >> 33557136

Design, Synthesis, and In Silico Multitarget Pharmacological Simulations of Acid Bioisosteres with a Validated In Vivo Antihyperglycemic Effect.

Elix Alberto Domínguez-Mendoza1, Yelzyn Galván-Ciprés1, Josué Martínez-Miranda1, Cristian Miranda-González1, Blanca Colín-Lozano1, Emanuel Hernández-Núñez2, Gloria I Hernández-Bolio2, Oscar Palomino-Hernández3,4, Gabriel Navarrete-Vazquez1.   

Abstract

Substituted phenylacetic (1-3), phenylpropanoic (4-6), and benzylidenethiazolidine-2,4-dione (7-9) derivatives were designed according to a multitarget unified pharmacophore pattern that has shown robust antidiabetic activity. This bioactivity is due to the simultaneous polypharmacological stimulation of receptors PPARα, PPARγ, and GPR40 and the enzyme inhibition of aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP-1B). The nine compounds share the same four pharmacophore elements: an acid moiety, an aromatic ring, a bulky hydrophobic group, and a flexible linker between the latter two elements. Addition and substitution reactions were performed to obtain molecules at moderated yields. In silico pharmacological consensus analysis (PHACA) was conducted to determine their possible modes of action, protein affinities, toxicological activities, and drug-like properties. The results were combined with in vivo assays to evaluate the ability of these compounds to decrease glucose levels in diabetic mice at a 100 mg/kg single dose. Compounds 6 (a phenylpropanoic acid derivative) and 9 (a benzylidenethiazolidine-2,4-dione derivative) ameliorated the hyperglycemic peak in a statically significant manner in a mouse model of type 2 diabetes. Finally, molecular dynamics simulations were executed on the top performing compounds to shed light on their mechanism of action. The simulations showed the flexible nature of the binding pocket of AR, and showed that both compounds remained bound during the simulation time, although not sharing the same binding mode. In conclusion, we designed nine acid bioisosteres with robust in vivo antihyperglycemic activity that were predicted to have favorable pharmacokinetic and toxicological profiles. Together, these findings provide evidence that supports the molecular design we employed, where the unified pharmacophores possess a strong antidiabetic action due to their multitarget activation.

Entities:  

Keywords:  diabetes; drug design; molecular dynamics; multitarget ligands

Mesh:

Substances:

Year:  2021        PMID: 33557136      PMCID: PMC7913794          DOI: 10.3390/molecules26040799

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  40 in total

1.  Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.

Authors:  Tahmeena Khan; Rumana Ahmad; Iqbal Azad; Saman Raza; Seema Joshi; Abdul Rahman Khan
Journal:  Comput Biol Chem       Date:  2018-05-08       Impact factor: 2.877

2.  The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.

Authors:  Jun He; Hao-Xue Gao; Na Yang; Xiao-Dong Zhu; Run-Bin Sun; Yuan Xie; Cai-Hong Zeng; Jing-Wei Zhang; Jian-Kun Wang; Fei Ding; Ji-Ye Aa; Guang-Ji Wang
Journal:  Acta Pharmacol Sin       Date:  2018-06-21       Impact factor: 6.150

3.  Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts.

Authors:  Deirdre A Buckley; Alan Cheng; Patrick A Kiely; Michel L Tremblay; Rosemary O'Connor
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice.

Authors:  Atsuo Tahara; Akiko Matsuyama-Yokono; Masayuki Shibasaki
Journal:  Eur J Pharmacol       Date:  2011-01-23       Impact factor: 4.432

Review 5.  Protein tyrosine phosphatase 1B inhibitors for diabetes.

Authors:  Theodore O Johnson; Jacques Ermolieff; Michael R Jirousek
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

6.  Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.

Authors:  Sergio Hidalgo-Figueroa; Juan J Ramírez-Espinosa; Samuel Estrada-Soto; Julio C Almanza-Pérez; Rubén Román-Ramos; Francisco J Alarcón-Aguilar; Jesús V Hernández-Rosado; Hermenegilda Moreno-Díaz; Daniel Díaz-Coutiño; Gabriel Navarrete-Vázquez
Journal:  Chem Biol Drug Des       Date:  2013-03-21       Impact factor: 2.817

7.  Ursolic acid derivatives as potential antidiabetic agents: In vitro, in vivo, and in silico studies.

Authors:  Ricardo Guzmán-Ávila; Virginia Flores-Morales; Paolo Paoli; Guido Camici; Juan José Ramírez-Espinosa; Litzia Cerón-Romero; Gabriel Navarrete-Vázquez; Sergio Hidalgo-Figueroa; Maria Yolanda Rios; Rafael Villalobos-Molina; Samuel Estrada-Soto
Journal:  Drug Dev Res       Date:  2018-01-29       Impact factor: 4.360

8.  An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.

Authors:  Rosanna Maccari; Antonella Del Corso; Paolo Paoli; Ilenia Adornato; Giulia Lori; Francesco Balestri; Mario Cappiello; Alexandra Naß; Gerhard Wolber; Rosaria Ottanà
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

9.  Synthesis and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study.

Authors:  Sergio Hidalgo-Figueroa; Samuel Estrada-Soto; Juan José Ramírez-Espinosa; Paolo Paoli; Giulia Lori; Ismael León-Rivera; Gabriel Navarrete-Vázquez
Journal:  Biomed Pharmacother       Date:  2018-08-29       Impact factor: 6.529

10.  In vitro screening for protein tyrosine phosphatase 1B and dipeptidyl peptidase IV inhibitors from selected Nigerian medicinal plants.

Authors:  Yusuf Saidu; Suleiman Alhaji Muhammad; Abdullahi Yahaya Abbas; Andrew Onu; Ibrahim Mohammed Tsado; Luba Muhammad
Journal:  J Intercult Ethnopharmacol       Date:  2016-12-22
View more
  2 in total

1.  Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors.

Authors:  Ádám Sipos; Eszter Szennyes; Nikolett Éva Hajnal; Sándor Kun; Katalin E Szabó; Karen Uray; László Somsák; Tibor Docsa; Éva Bokor
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-15

2.  Kinetic and Molecular Docking Studies to Determine the Effect of Inhibitors on the Activity and Structure of Fused G6PD::6PGL Protein from Trichomonas vaginalis.

Authors:  Víctor Martínez-Rosas; Beatriz Hernández-Ochoa; Gabriel Navarrete-Vázquez; Carlos Martínez-Conde; Fernando Gómez-Chávez; Laura Morales-Luna; Abigail González-Valdez; Roberto Arreguin-Espinosa; Sergio Enríquez-Flores; Verónica Pérez de la Cruz; Rodrigo Aguayo-Ortiz; Carlos Wong-Baeza; Isabel Baeza-Ramírez; Saúl Gómez-Manzo
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.